Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418)

Haeyoung Kim, Won Park, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Yeon Joo Kim, Eun Sook Lee, Keun Seok Lee, Han Sung Kang, In Hae Park, Kyung Hwan Shin, Kyubo Kim, Kyung Ran Park, Yongbae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung Sik Lee, Jung Soo KimJong Young Lee

Research output: Contribution to journalArticle

Abstract

Background and Purpose: This study was performed to determine optimal radiation dose in pN1 breast cancer patients who received breast conserving surgery (BCS) and anthracycline plus taxane (AT)-based chemotherapy. Materials and Methods: Retrospective chart reviews were performed in 1,147 patients who were treated between January 2006 and December 2010. The impact of radiation dose on treatment outcomes was evaluated. Results: Median follow-up time was 66 months. The 5-year rate of disease-free survival (DFS) was 93.2%. Larger tumor size (> 20 mm), positive lymphovascular invasion, high histologic grade, and high ratio of positive nodes (> 0.1) were significantly associated with inferior DFS. By using the 4 factors related to DFS, patients were categorized into high-risk (with ≥ 3 factors) and low-risk (with < 3 factors) groups. In the high-risk group, higher radiation dose (> 60.3 GyEQD2) was significantly associated with better DFS than the lower dose (≤ 60.3 GyEQD2). However, the radiation dose did not impact DFS in the low-risk group. Conclusions: Dosing of radiation affects the outcome of post-BCS radiotherapy in pN1 breast cancer. Doses of over 60.3 GyEQD23 were associated with better outcome in the high-risk patients.

Original languageEnglish
Pages (from-to)1796-1804
Number of pages9
JournalOncotarget
Volume8
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Segmental Mastectomy
Anthracyclines
Disease-Free Survival
Lymph Nodes
Radiation
Breast Neoplasms
Drug Therapy
Radiotherapy
taxane
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kim, Haeyoung ; Park, Won ; Yu, Jeong Il ; Choi, Doo Ho ; Huh, Seung Jae ; Kim, Yeon Joo ; Lee, Eun Sook ; Lee, Keun Seok ; Kang, Han Sung ; Park, In Hae ; Shin, Kyung Hwan ; Kim, Kyubo ; Park, Kyung Ran ; Kim, Yongbae ; Ahn, Sung Ja ; Lee, Jong Hoon ; Kim, Jin Hee ; Chun, Mison ; Lee, Hyung Sik ; Kim, Jung Soo ; Lee, Jong Young. / Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy : A retrospective multicenter analysis (KROG 1418). In: Oncotarget. 2017 ; Vol. 8, No. 1. pp. 1796-1804.
@article{f4a6f2b76fcc41e9ae1e855326ebb519,
title = "Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418)",
abstract = "Background and Purpose: This study was performed to determine optimal radiation dose in pN1 breast cancer patients who received breast conserving surgery (BCS) and anthracycline plus taxane (AT)-based chemotherapy. Materials and Methods: Retrospective chart reviews were performed in 1,147 patients who were treated between January 2006 and December 2010. The impact of radiation dose on treatment outcomes was evaluated. Results: Median follow-up time was 66 months. The 5-year rate of disease-free survival (DFS) was 93.2{\%}. Larger tumor size (> 20 mm), positive lymphovascular invasion, high histologic grade, and high ratio of positive nodes (> 0.1) were significantly associated with inferior DFS. By using the 4 factors related to DFS, patients were categorized into high-risk (with ≥ 3 factors) and low-risk (with < 3 factors) groups. In the high-risk group, higher radiation dose (> 60.3 GyEQD2) was significantly associated with better DFS than the lower dose (≤ 60.3 GyEQD2). However, the radiation dose did not impact DFS in the low-risk group. Conclusions: Dosing of radiation affects the outcome of post-BCS radiotherapy in pN1 breast cancer. Doses of over 60.3 GyEQD23 were associated with better outcome in the high-risk patients.",
author = "Haeyoung Kim and Won Park and Yu, {Jeong Il} and Choi, {Doo Ho} and Huh, {Seung Jae} and Kim, {Yeon Joo} and Lee, {Eun Sook} and Lee, {Keun Seok} and Kang, {Han Sung} and Park, {In Hae} and Shin, {Kyung Hwan} and Kyubo Kim and Park, {Kyung Ran} and Yongbae Kim and Ahn, {Sung Ja} and Lee, {Jong Hoon} and Kim, {Jin Hee} and Mison Chun and Lee, {Hyung Sik} and Kim, {Jung Soo} and Lee, {Jong Young}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.12882",
language = "English",
volume = "8",
pages = "1796--1804",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "1",

}

Kim, H, Park, W, Yu, JI, Choi, DH, Huh, SJ, Kim, YJ, Lee, ES, Lee, KS, Kang, HS, Park, IH, Shin, KH, Kim, K, Park, KR, Kim, Y, Ahn, SJ, Lee, JH, Kim, JH, Chun, M, Lee, HS, Kim, JS & Lee, JY 2017, 'Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418)', Oncotarget, vol. 8, no. 1, pp. 1796-1804. https://doi.org/10.18632/oncotarget.12882

Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy : A retrospective multicenter analysis (KROG 1418). / Kim, Haeyoung; Park, Won; Yu, Jeong Il; Choi, Doo Ho; Huh, Seung Jae; Kim, Yeon Joo; Lee, Eun Sook; Lee, Keun Seok; Kang, Han Sung; Park, In Hae; Shin, Kyung Hwan; Kim, Kyubo; Park, Kyung Ran; Kim, Yongbae; Ahn, Sung Ja; Lee, Jong Hoon; Kim, Jin Hee; Chun, Mison; Lee, Hyung Sik; Kim, Jung Soo; Lee, Jong Young.

In: Oncotarget, Vol. 8, No. 1, 01.01.2017, p. 1796-1804.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy

T2 - A retrospective multicenter analysis (KROG 1418)

AU - Kim, Haeyoung

AU - Park, Won

AU - Yu, Jeong Il

AU - Choi, Doo Ho

AU - Huh, Seung Jae

AU - Kim, Yeon Joo

AU - Lee, Eun Sook

AU - Lee, Keun Seok

AU - Kang, Han Sung

AU - Park, In Hae

AU - Shin, Kyung Hwan

AU - Kim, Kyubo

AU - Park, Kyung Ran

AU - Kim, Yongbae

AU - Ahn, Sung Ja

AU - Lee, Jong Hoon

AU - Kim, Jin Hee

AU - Chun, Mison

AU - Lee, Hyung Sik

AU - Kim, Jung Soo

AU - Lee, Jong Young

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background and Purpose: This study was performed to determine optimal radiation dose in pN1 breast cancer patients who received breast conserving surgery (BCS) and anthracycline plus taxane (AT)-based chemotherapy. Materials and Methods: Retrospective chart reviews were performed in 1,147 patients who were treated between January 2006 and December 2010. The impact of radiation dose on treatment outcomes was evaluated. Results: Median follow-up time was 66 months. The 5-year rate of disease-free survival (DFS) was 93.2%. Larger tumor size (> 20 mm), positive lymphovascular invasion, high histologic grade, and high ratio of positive nodes (> 0.1) were significantly associated with inferior DFS. By using the 4 factors related to DFS, patients were categorized into high-risk (with ≥ 3 factors) and low-risk (with < 3 factors) groups. In the high-risk group, higher radiation dose (> 60.3 GyEQD2) was significantly associated with better DFS than the lower dose (≤ 60.3 GyEQD2). However, the radiation dose did not impact DFS in the low-risk group. Conclusions: Dosing of radiation affects the outcome of post-BCS radiotherapy in pN1 breast cancer. Doses of over 60.3 GyEQD23 were associated with better outcome in the high-risk patients.

AB - Background and Purpose: This study was performed to determine optimal radiation dose in pN1 breast cancer patients who received breast conserving surgery (BCS) and anthracycline plus taxane (AT)-based chemotherapy. Materials and Methods: Retrospective chart reviews were performed in 1,147 patients who were treated between January 2006 and December 2010. The impact of radiation dose on treatment outcomes was evaluated. Results: Median follow-up time was 66 months. The 5-year rate of disease-free survival (DFS) was 93.2%. Larger tumor size (> 20 mm), positive lymphovascular invasion, high histologic grade, and high ratio of positive nodes (> 0.1) were significantly associated with inferior DFS. By using the 4 factors related to DFS, patients were categorized into high-risk (with ≥ 3 factors) and low-risk (with < 3 factors) groups. In the high-risk group, higher radiation dose (> 60.3 GyEQD2) was significantly associated with better DFS than the lower dose (≤ 60.3 GyEQD2). However, the radiation dose did not impact DFS in the low-risk group. Conclusions: Dosing of radiation affects the outcome of post-BCS radiotherapy in pN1 breast cancer. Doses of over 60.3 GyEQD23 were associated with better outcome in the high-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=85009820816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009820816&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.12882

DO - 10.18632/oncotarget.12882

M3 - Article

AN - SCOPUS:85009820816

VL - 8

SP - 1796

EP - 1804

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1

ER -